INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 54 filers reported holding INOZYME PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,334,112 | -19.9% | 1,270,027 | +6.3% | 2.11% | +4.7% |
| Q2 2023 | $6,656,301 | -13.5% | 1,195,027 | -11.0% | 2.02% | -1.1% |
| Q1 2023 | $7,690,754 | +232.2% | 1,342,191 | -39.1% | 2.04% | +231.0% |
| Q4 2022 | $2,315,120 | -56.7% | 2,204,876 | +10.4% | 0.62% | -57.1% |
| Q3 2022 | $5,350,000 | -44.9% | 1,996,277 | -1.8% | 1.44% | -61.2% |
| Q2 2022 | $9,701,000 | +165.9% | 2,033,802 | +128.0% | 3.70% | +138.7% |
| Q1 2022 | $3,649,000 | -40.0% | 892,057 | 0.0% | 1.55% | -23.1% |
| Q4 2021 | $6,084,000 | -43.0% | 892,057 | -3.1% | 2.02% | -35.1% |
| Q3 2021 | $10,666,000 | -32.5% | 920,264 | -0.8% | 3.11% | -15.3% |
| Q2 2021 | $15,801,000 | -13.9% | 927,264 | 0.0% | 3.68% | 0.0% |
| Q1 2021 | $18,360,000 | -10.6% | 927,264 | -6.8% | 3.68% | -36.5% |
| Q4 2020 | $20,545,000 | -22.6% | 995,396 | -1.4% | 5.79% | -38.7% |
| Q3 2020 | $26,529,000 | – | 1,009,117 | – | 9.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |